

MAY 7 2003
TECHATENT 7 2003
TICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

D. Williams et al.

SERIAL NO.:

09/506,362

GROUP: 1624

FILED:

February 15, 2000

EXAMINER: J. Ford

FOR:

APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL

1. Transmitted herewith is an Amendment for this application.

STATUS

2.	Appli	cant is
	[]	a small entity. A statement:
		[] is attached.
		[] was already filed.
	[X]	other than a small entity.

EXTENSION OF TERM

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) — If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

X deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

FACSIMILE

transmitted by facsimile to the Patent and Trademark Office.

Signature

Susan M. Dillon

(type or print name of person certifying)

Susar on Oullon

(Amendment Transmittal—page 1 of 4)

Date: April 29, 2003

	unless i	the timely-filed response p	d/or entry of an additional amendment after ex laced the application in condition for allowar atutory period, the period has ceased to run."	nce. Of course, if a Notice of Appeal has		
NOTE:		37 C.F.R. § 1.645 for extensions of time in interference proceedings, and 37 C.F.R. § 1.550(c) for extensions of time in xamination proceedings.				
3.	The pr	The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136 apply.				
			(complete (a) or (b), as applicable)			
	(a)		petitions for an extension of time under F.R. § 1.17(a)(1)-(4)) for the total num	•		
	[]	Extension (months) one month two months three months four months	Fee for other than small entity \$ 110.00 \$ 400.00 \$ 920.00 \$ 1,440.00	Fee for small entity \$ 55.00 \$ 200.00 \$ 460.00 \$ 720.00		
			Fee: \$	-		
If an ac	lditiona	l extension of time is a	required, please consider this a petition	n therefor.		
		(check	and complete the next item, if applica	ble)		
	[]		months has already been secured deducted from the total fee due for the	<u> </u>		
		Extension f	ee due with this request \$			

OR

(b) [X] Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently overlooked the need for a petition for extension of time.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. § 1.16(b)-(d)) has been calculated as shown below:

(Col.1)		(Col. 2) (Col. 3) SMALL E			ITY_		S	OTHER THAN A		
	Claims									
	Remaining	Highest No.								
After		Previously	Present	nt Addit.					Addit.	
	Amendment	Paid For	Extra	Rate	F	ee	OR	Rate	Fee	
Total	Minus		=	x \$9 =	\$			x \$18 =	\$	
ndep.	Minus		=	x \$39 =	\$			x \$78 =	\$	
] Firs	t Presentation of Mu	ltiple Depender	nt Claim	+ \$130 =	= \$			+ \$260 =	\$	
			<u>=</u> .	Total			OR	Total		
				Addit. Fee	\$	0.00)	Addit. Fee	\$	
* IC4L	ne entry in Col. 1 is less the	on the entry in Co	d 2 write "C	O" in Col 3						

^{***} If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed.

WARNING: "After final rejection or action (§ 1.113) amendments may be made canceling claims or complying with any requirement of form which has been made." 37 C.F.R. § 1.116(a) (emphasis added).

(complete (c) or (d), as applicable)

(c) [X] No additional fee for claims is required.

OR

(d) [] Total additional fee for claims required \$ _____.

FEE PAYMENT

5.	[]	Attached is a check in the sum of \$
	[]	Charge Account No the sum of \$
		A duplicate of this transmittal is attached.

FEE DEFICIENCY

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, (1065 O.G. 31-33).

6. [X] If any additional extension and/or fee is required, charge Account No. <u>04-1105</u>.

AND/OR

[X] If any additional fee for claims is required, charge Account No. __04-1105____.

SIGNATURE OF PRACTITIONER

Chine Com

Reg. No.38,256 Christine C. O'Day

(type or print name of practitioner)
EDWARDS & ANGELL LLP
Tel. No: 617-439-4444
P.O. Box 9169

P.O. Box 9169 Boston, MA 02209





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#240

APPLICANT:

D. Williams, et al.

SERIAL NO.:

09/506,362

ART UNIT: 1624

FILED:

February 15, 2000

EXAMINER: J. Ford

FOR:

APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

AMENDMENT

In response to the Office Action issued on January 31, 2003, Applicants kindly request that the application be amended as follows:

IN THE CLAIMS:

Kindly add the following new claim:

- 48. A method of claim 45 wherein the compound is selected from the group consisting of:
- 4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
- 7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
- 4 [(Dimethyl carbamoyl) oxy] 5 phenylnaphto [2,3-b] pyrrolo [1,2-d] [1,4] oxazepine,
- 7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
- 7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,
- 7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
- 7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
- 7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,
- 4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,